Showing posts sorted by relevance for query breast cancer. Sort by date Show all posts
Showing posts sorted by relevance for query breast cancer. Sort by date Show all posts

Thursday, October 03, 2024

 

New ACS report: Breast cancer mortality continues three decade decline overall, but steeper increases in incidence for women <50 & Asian American, Pacific Islanders of all ages




American Cancer Society
ACS Breast Cancer Statistics Report 2024 

image: 

Breast Cancer Report from the American Cancer Society

view more 

Credit: American Cancer Society




The American Cancer Society (ACS) today released Breast Cancer Statistics, 2024, the organization’s biennial update on breast cancer occurrence and trends in the United States. The new report finds breast cancer mortality rates overall have dropped by 44% since 1989, averting approximately 517,900 breast cancer deaths. However, not all women have benefited from this progress, notably American Indian and Alaska Native (AIAN) women, whose rates have remained unchanged over the past three decades. Also concerning is the continued upward trend in breast cancer incidence, rising by 1% annually during 2012-2021, with the steepest increase in women younger than 50 years (1.4% per year) and Asian American/Pacific Islander (AAPI) women of any age (2.5%-2.7% per year). These important findings are published in CA: A Cancer Journal for Cliniciansalongside its consumer-friendly companion, Breast Cancer Facts & Figures 2024, available on cancer.org.

“The encouraging news is breast cancer mortality rates continue to decrease thanks to advances in early detection and treatment,” said Angela Giaquinto, associate scientist, cancer surveillance research at the American Cancer Society and lead author of the study. “But future progress may be thwarted by increasing incidence, especially among younger women, and consequences of the COVID-19 pandemic, such as delayed diagnosis due to interruptions in screening.”

Breast cancer is the most common cancer among U.S. women after skin cancer and the leading cause of cancer death in Hispanic women. In 2024, an estimated 310,720 new cases of invasive breast cancer will be diagnosed in women, and approximately 42,250 women are expected to die from the disease. While rare, this year, 2,790 men will also be diagnosed with breast cancer, and 530 men will die from the disease.

For the report, researchers analyzed population-based cancer incidence and mortality data collected by the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program, the Centers for Disease Control and Prevention’s National Program of Cancer Registries (NPCR), and the National Center for Health Statistics. Combined SEER and NPCR data provided by the North American Association of Central Cancer Registries (NAACCR) were the source for short-term incidence trends (1998-2021) and contemporary incidence rates (2017–2021) by race and ethnicity, age, molecular subtype, state, and stage (SEER Summary).

“Women today are a lot less likely to die from breast cancer, but alarming disparities still remain, especially for Asian American, Pacific Islander, Native American and Black women,” said Dr. William Dahut, chief scientific officer at the American Cancer Society. “These gaps need to be rectified through systematic efforts to ensure access to high-quality screening and treatment for every woman.”

Other key findings from the report include:

  • AIAN women have 10% lower breast cancer incidence than White women, but 6% higher mortality, and only 51% of AIAN women 40 years or older had a mammogram in the past two years compared to 68% of White women. 
  • Breast cancer in women under 50 years has increased in AAPI women by 50% since 2000, surpassing the rate in young Hispanic, AIAN, and Black women to become the highest rate alongside White women (both 86 per 100,000).
  • Black women continue to have a 38% higher breast cancer mortality rate than White women, despite a 5% lower incidence. Black women also have lower survival than White women for every breast cancer subtype and stage of diagnosis except localized disease, with which they are 10% less likely to be diagnosed (58% versus 68%).

To address ongoing cancer disparities in Black women, the ACS launched the VOICES of Black Women study in May 2024. The study aims to enroll over 100,000 Black women in the U.S. between the ages of 25 and 55 from diverse backgrounds and income levels who have not been diagnosed with cancer to better understand cancer risk and outcomes. For more information and to participate, visit voices.cancer.org.

“Building upon the progress we have made in reducing breast cancer mortality rates requires ensuring more individuals have access to breast cancer screenings,” said Lisa A. Lacasse, president of the American Cancer Society Cancer Action Network (ACS CAN), the advocacy affiliate of the American Cancer Society. “Through cooperative agreements with all 50 states, tribal organizations and territories, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) has been a lifeline for limited-income, uninsured and underinsured women, providing them with critical screenings and treatment. Congress has a chance to pass the Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act, which would reauthorize the NBCCEDP and expand its reach to more people who may not otherwise be screened. We urge Congress to take this step towards saving lives from cancer while reducing costs for our health care system.”

Rebecca Siegel is senior author of the report. Other ACS authors participating in the study include Dr. Ahmedin JemalDr. Hyuna SungJessica Star and Dr. Robert Smith.

More information on breast cancer can be found here.

# # #

About the American Cancer Society
The American Cancer Society is the leading cancer-fighting organization with a vision to end cancer as we know it for everyone. For more than 110 years, we have been the only organization improving the lives of people with cancer and their families through advocacy, research, and patient support, to ensure that everyone has an opportunity to prevent, detect, treat, and survive cancer. To learn more, visit cancer.org or call our 24/7 helpline at 1-800-227-2345. Connect with us on Facebook, X, and Instagram.
 

Sunday, April 19, 2026

 

New guidance from ACP says all average-risk females aged 50-74 should undergo biennial mammography screening for breast cancer



ACP also offers screening advice for females aged 40-49, frequency of screening, discontinuing screening, and females with dense breasts





American College of Physicians





SAN FRANCISCO, April 17, 2026 – New guidance from the American College of Physicians (ACP) says all asymptomatic, average-risk females ages 50 to 74 should receive biennial screening mammography for breast cancer. Females between the ages of 40 and 49 should discuss with their doctor their risk for breast cancer and the benefits and harms of screening. This is because harms of screening such as false positive results, psychological distress because of it, overdiagnosis, overtreatment, additional testing, and radiation exposure may outweigh the uncertain benefits in this population. ACP's advice, "Screening for Breast Cancer in Asymptomatic, Average-Risk Adult Females: A Guidance Statement from the American College of Physicians", is published in Annals of Internal Medicine. 

ACP also provides guidance on when to discontinue breast cancer screening and how to approach screening for females with dense breasts. ACP says that asymptomatic, average‑risk females who are 75 years or older, or those with a limited life expectancy, discuss stopping routine screening with their doctor. This is because the benefits of screening beyond age 74 are reduced or uncertain, while potential harms, such as overdiagnosis, become more likely with increasing age. For asymptomatic, average‑risk females who have dense breasts, ACP advises doctors to consider supplemental digital breast tomosynthesis (DBT). Decisions should consider potential benefits and harms, radiation exposure, availability, patient values and preferences, and cost. However, ACP advises against using supplemental MRI or ultrasound for screening in this population. 

The guidance statement was developed by ACP’s Clinical Guidelines Committee which defined average risk as females who do not have a personal history of breast cancer or diagnosis of a high-risk breast lesion, a genetic mutation such as BRCA 1 or 2 that is known to increase risk, another familial breast cancer risk syndrome, or a history of high-dose radiation therapy to the chest at a young age. 

“Screening for breast cancer is essential and should be guided by the best available evidence" said Jason M. Goldman, MD, MACP, President of ACP. "ACP developed this guidance to provide physicians and females with the information they need to make breast cancer screening decisions, including when to start and discontinue, how often to screen, and which methods to use for screening."   

Saturday, March 08, 2025

 

Breast cancer death rates have stopped going down


\

Oxford University Press USA




A new paper in the Journal of Breast Imaging, published by Oxford University Press, indicates that breast cancer mortality rates have stopped declining in women older than age 74, and reconfirms that breast cancer mortality rates have stopped falling in women younger than age 40. This finding for older women is new.

Breast cancer is the second leading cause of cancer deaths in American women, with over 42,000 women dying of the disease in 2024. Before 1990, female breast cancer rates had been rising, and breast cancer mortality rates had been flat or increasing. Since 1990 there has been a steady decline in breast cancer mortality rates, which public health observers attribute both to the widespread use of mammograms and improvements in treatment.

The researchers, Debra Monticciolo and R. Edward Hendrick, assessed cancer mortality rates collected and maintained by the National Center for Health Statistics since 1990. For U.S. women overall breast cancer mortality rates have decreased steadily from 1990 to 2022, falling by 43.5% over that period. The most recent trend has been a decrease of 1.23% per year from 2010 to 2022, the lowest rate of decrease recorded since 1990. For U.S. women ages 20 to 39 (combining all races/ethnicities), breast cancer mortality rates decreased by 2.79% per year from 1990 until 2010, but have remained flat since 2010.

The investigation found that for women 75 years and older, the breast cancer mortality rate decreased by 1.26% per year from 1993 to 2013, when the rate stopped declining. For Asian, Hispanic, and Native American women (of all ages), breast cancer mortality rates have stopped declining over the most recent period: since 2009 for Asian women, since 2008 for Hispanic women, and since 2005 for Native American women.

Previous research indicated that breast cancer mortality rates stopped declining for women under 40 in 2010. The researchers here found that in both younger and older groups, the end of mortality rate decline was primarily due to mortality rates no longer declining for White women under 40 and over 74, as well as unfavorable trends for Hispanic women ages 20-39 years and for Asian, Hispanic, and Native American women 75 and older. Breast cancer mortality rates in Black women continued to decline in all age groups.

The investigators conducting this study contend that mortality rates have stopped declining for women under 40 and over 74 due to significant increases in stage IV breast cancers at diagnosis in these two age groups. Stage IV (metastatic) breast cancer at diagnosis has an extremely poor prognosis: a 31% 5-year survival rate.

This study indicates that increasing rates of advanced stage breast cancer at diagnosis is an important reason breast cancer mortality rates are no longer declining at the rate they once did. The researchers believe that this may be due to healthcare protocols. While the medical community currently recommends a breast cancer assessment for all women by age 25, breast cancer screening is only recommended for women under age 40 who are at higher-than-average risk. Some guidelines discourage women over 74 from screening.

Breast cancer mortality rate ratios for Black vs White women show the widest gap for women under age 40 years, suggesting that younger Black women are especially in need of alternatives to our current breast cancer risk assessment, screening, and treatment strategies, according to the authors.

“The fact that breast cancer mortality rates have stopped declining for women over age 74 is an alarming new trend,” said Monticciolo. “This is in addition to women under age 40 no longer seeing mortality rates decline from breast cancer. These groups are exactly those discouraged from breast cancer screening by some U.S. guidelines.”

The paper, “Recent Trends in Breast Cancer Mortality Rates for U.S. Women by Age and Race/Ethnicity,” is available (at midnight on March 6th) at https://doi.org/10.1093/jbi/wbaf007.

To request a copy of the study, please contact:
Daniel Luzer 
daniel.luzer@oup.com

Tuesday, August 04, 2026

 

NICE referral criteria miss up to 95% of women under 50 who go on to develop breast cancer within 10 years





University of Cambridge




The National Institute for Health and Care Excellence (NICE) criteria used to decide who should be referred by GPs for further breast cancer risk assessment and specialist care misses up to 95% of women under 50 who will go on to develop the disease in the next 10 years, new research by researchers at the University of Cambridge and The Institute of Cancer Research, London, has found.

Using BOADICEA – a comprehensive risk assessment tool developed at the University of Cambridge with funding from Cancer Research UK – researchers identified eight times as many women in this age group who developed breast cancer as the NICE criteria.

Breast cancer is the most common cancer worldwide, with steady increases in incidence over the last decades. It accounts for around one in four cases of cancers and 15% of cancer deaths in women, and is one of the leading causes of death in women under 50. Identifying women at higher risk can allow for additional screening or preventive treatment.

In England, most women at higher risk of breast cancer are identified after being referred by their GP for further assessment and specialist care. The assessment with their GP is based on family history, following criteria set out by NICE.

However, in research published today in the British Journal of Cancer, a team of researchers showed that the NICE criteria fail to identify as many as 95% of women under 50 who are at higher-than-average risk of breast cancer and 95% of women who go on to develop breast cancer within 10 years.

The team analysed data from 1,258 women aged under 50 years recruited to the Breast Cancer Now Generations Study between 2004 and 2011.

They compared how good the NICE criteria and several risk assessment approaches using the BOADICEA risk model were at identifying those women who would go on to develop breast cancer. BOADICEA combines factors such as family history, lifestyle, reproductive history and genetic information.

Previous studies have shown that multifactorial risk models can identify more women at increased risk of breast cancer than family history alone. This is the first study to directly evaluate this approach in a UK population-based cohort of women under 50.

Completing a risk assessment with the full BOADICEA model for all women aged under 50 would result in 26.5% of women being categorised as at above-population level risk and referred for further assessment. This would include 34.8% of women under 50 who develop breast cancer within 10 years.

By comparison, the current NICE criteria would result in 1.4% of women under 50 being referred for further assessment, which would include just 4.4% of those women who develop breast cancer.

A main reason for the disparity, say the researchers, is because three-quarters of women (73%) under 50 years who develop breast cancer within 10 years have no family history of breast cancer, the key criterion in the NICE guidelines.

Dr Juliet Usher-Smith from the Department of Public Health and Primary Care, University of Cambridge, the study’s senior author, said: “We need to get better at identifying women at highest risk of breast cancer so that we can intervene early, when there are more options for treating, or even preventing, their disease.

“The current NICE criteria used in general practice are missing up to 95% of women under 50 who will go on to develop breast cancer. It’s time to look again at these criteria in the light of our findings.”

The researchers recognise that changing the criteria – offering the full BOADICEA risk assessment to all women under 50, for example – would be far more resource intensive and lead to more referrals, many of whom will not develop breast cancer.

Professor Montserrat Garcia-Closas from The Institute of Cancer Research, London, said: “There will be a balance to strike: the NICE criteria are much easier to implement, but miss a large proportion of women at elevated risk. But a full risk assessment including genetic testing will place a heavy burden on resources.

“Ultimately, it will be a trade-off between the practical, resource, and cost implications of data collection and risk assessment, and the potential benefits and harms associated with accurate and inaccurate classification of women.”

A second study from the team, also published in the British Journal of Cancer, found strong support among the public for proactive approaches to breast cancer risk assessment for women aged 30–49, rather than waiting for women to come forward with concerns about their family history.

Women preferred proactive invitations, rather than having to ask their GP, and supported the use of approaches that identify more women at higher risk, even if this requires more assessments, including genetic testing. The most popular options were those that invited all women for assessment and used more comprehensive risk tools, such as BOADICEA.

The next step is to test how multifactorial risk assessment could be implemented safely, equitably, and cost-effectively in routine care. This is being evaluated by multiple groups, including UK-based research led by Dr Usher-Smith and colleagues in Cambridge on breast cancer risk assessment in general practice.

The research was supported by Cancer Research UK and Breast Cancer Now.

Dr Simon Vincent, chief scientific officer at Breast Cancer Now, said: “Finding new ways to identify women at increased risk could help to prevent some breast cancers or detect them earlier, when treatment is more likely to be successful.

“These findings highlight the limitations of NICE’s current referral criteria, and so this research must now be carefully considered as part of the current review of its Family History guidelines. However, it’s equally important that any changes come with the needed investment in family history services, so they can be implemented effectively and fairly across the NHS.

“Overall, this study highlights the value of long-term research like the Breast Cancer Now Generations Study, which is helping us better understand who is most at risk of developing breast cancer and why.”    

Dr Sowmiya Moorthie, senior strategic evidence manager at Cancer Research UK, said: “Exploring different ways to identify women with a higher risk of breast cancer could help people receive more personalised care.

“The current UK approach, which relies on women under 50 self-presenting, misses many women with a higher risk of breast cancer who could benefit from targeted support and guidance on how to manage their risk. Further research is needed, however, to understand the impact of adopting a different approach, including on staffing and equipment. Any changes must be accessible and equitable, taking into consideration the anxiety that extra referrals might cause for women.

“Everyone can take steps to reduce their cancer risk, such as maintaining a healthy weight and cutting back on alcohol. Anyone who notices a change that is unusual for them should speak to their GP, as early diagnosis can improve outcomes.”

Reference

Frost, R, et al. Comparison of NICE criteria with the BOADICEA multifactorial risk model to guide breast cancer risk assessment and referral amongst women under age 50 within primary care. BJC; 4 Aug 2026; DOI: 10.1038/s41416-026-03547-2

Dennison, RA, et al. Priorities for breast cancer risk assessment in UK women under age 50: A survey and discrete choice experiment. BJC; 4 Aug 2026; DOI: 10.1038/s41416-026-03546-3